Evidence map›Paper›PMID 39822269›Full record

ArticleOpen forum infectious diseases2025

An Observational Study to Determine the Prevalence of COVID-19 Among Hospitalized Patients With Multidrug-Resistant Enterobacterales Infections and Clinical Outcomes, 10 US Sites, 2020--2022.

Julian E Grass, Sandra N Bulens, Uzma A Ansari, Nadezhda Duffy, Jesse T Jacob, Gillian Smith, Paulina A Rebolledo, Ana Mesa Restrepo, Elisabeth Vaeth, Ghinwa Dumyati and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Julian E GrassDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-1454-7440
Sandra N BulensDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4809-665X
Uzma A AnsariDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Nadezhda DuffyDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-2347-3690
Jesse T JacobEmory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-9811-6260
Gillian SmithEmory University School of Medicine, Atlanta, Georgia, USA.
Paulina A RebolledoEmory University School of Medicine, Atlanta, Georgia, USA.
Ana Mesa RestrepoEmory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-0807-1199
Elisabeth VaethMaryland Department of Health, Baltimore, Maryland, USA.
Ghinwa DumyatiNew York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0002-3634-2841
Rebecca TsayNew York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0003-2726-3807
Hsioa Che LooiNew York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York, USA.
Erin PhippsUniversity of New Mexico, Albuquerque, New Mexico, USA.
Kristina G FloresUniversity of New Mexico, Albuquerque, New Mexico, USA.ORCID https://orcid.org/0000-0003-3262-5462
Christopher WilsonTennessee Department of Health, Nashville Tennessee, USA.
Daniel MuletaTennessee Department of Health, Nashville Tennessee, USA.
Christopher A CzajaColorado Department of Public Health and Environment, Denver, Colorado, USA.ORCID https://orcid.org/0000-0002-1742-514X
Jennifer DriscollColorado Department of Public Health and Environment, Denver, Colorado, USA.
Helen JohnstonColorado Department of Public Health and Environment, Denver, Colorado, USA.
Ruth LynfieldMinnesota Department of Health, St Paul, Minnesota, USA.
Sean O'MalleyMinnesota Department of Health, St Paul, Minnesota, USA.
Meghan MaloneyConnecticut Department of Public Health, Hartford, Connecticut, USA.ORCID https://orcid.org/0009-0001-2917-4085
Nicole StabachConnecticut Department of Public Health, Hartford, Connecticut, USA.
Joelle NadleCalifornia Emerging Infections Program, Oakland, California, USA.
Rebecca PierceOregon Public Health Division, Oregon Health Authority, Portland, Oregon, USA.
Heather HertzelOregon Public Health Division, Oregon Health Authority, Portland, Oregon, USA.ORCID https://orcid.org/0009-0004-8468-9438
Alice Y GuhDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-3141-2089

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We investigated hospitalized carbapenem-resistant Enterobacterales (CRE) and extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) cases with and without COVID-19, as identified through Emerging Infections Program surveillance in 10 sites from 2020 to 2022. Methods: We defined a CRE case as the first isolation of Results: Of 1595 CRE and 1866 ESBL-E hospitalized cases, 38 (2.4%) and 60 (3.2%), respectively, had a SC2 Conclusions: CRE and ESBL-E infections among hospitalized patients with preceding COVID-19 were uncommon but had worse outcomes when compared with cases without COVID-19. COVID-19 prevention in patients at risk of CRE and ESBL-E infections is needed, as well as continued infection control measures and antibiotic stewardship for patients with COVID-19.

Indexed as

carbapenem-resistant EnterobacteralesCOVID-19extended spectrum beta-lactamase-producing EnterobacteralesSARS-CoV-2

Identifiers

PMID39822269
PMCPMC11736413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.